Both in Pharmaceuticals
Pacira BioSciences vs Ultragenyx Pharmaceutical
Over the past year PCRX returned +63.1% and RARE returned −53.4%; their daily moves had a correlation of 0.10.
PCRX +63.1% RARE −53.4%Growth of $1, one year, split-adjusted
| Metric | PCRX | RARE |
|---|---|---|
| Price | $36.31 | $14.92 |
| Market cap | $1.45B | $1.47B |
| Today | −0.11% | −2.48% |
| 1 month | +47.1% | +9.6% |
| 6 months | +52.9% | −39.3% |
| Year to date | +40.3% | −35.1% |
| 1 year | +62.5% | −52.6% |
| Revenue growth (YoY) | +6.2% | +28.1% |
| Gross margin | 77.0% | 84.1% |
| Net margin | 2.4% | −43.0% |
| P/E (TTM) | 99.0× | — |
| Price / sales | 1.9× | 2.1× |
| Net cash | -$112.1M | $292.0M |
| Dividend yield | — | — |
| Volatility (60d) | 82.8% | 127.6% |
| Short % of float | 21.2% | 21.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).